NewLink Genetics (NASDAQ:NLNK) Trading Down 5.8%

NewLink Genetics Corp (NASDAQ:NLNK)’s share price was down 5.8% during trading on Tuesday . The company traded as low as $1.43 and last traded at $1.47, approximately 1,184,716 shares were traded during trading. An increase of 126% from the average daily volume of 523,706 shares. The stock had previously closed at $1.56.

NLNK has been the topic of a number of recent research reports. Bank of America lowered NewLink Genetics from a “neutral” rating to an “underperform” rating in a research report on Friday, January 3rd. ValuEngine raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, February 16th.

The stock’s 50 day moving average price is $1.80 and its two-hundred day moving average price is $1.69. The stock has a market cap of $58.28 million, a price-to-earnings ratio of -1.32 and a beta of 1.24.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ladenburg Thalmann Financial Services Inc. boosted its holdings in NewLink Genetics by 2,739.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,365 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of NewLink Genetics during the 4th quarter valued at about $33,000. Jane Street Group LLC purchased a new position in shares of NewLink Genetics during the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC raised its stake in shares of NewLink Genetics by 70.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 34,712 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 14,395 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of NewLink Genetics by 479.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 95,164 shares of the biotechnology company’s stock valued at $241,000 after buying an additional 78,748 shares during the period. Institutional investors own 32.32% of the company’s stock.

NewLink Genetics Company Profile (NASDAQ:NLNK)

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Article: How interest rates affect municipal bond prices

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.